title: The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
abstract: We examined the efficacy of reduced-intensity conditioning (RIC) and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic leukemia (ALL) in first or second complete remission. RIC conditioning included busulfan 9 mg/kg or less (27), melphalan 150 mg/m(2) or less (23), low-dose total body irradiation (TBI; 36), and others (7). The RIC group was older (median 45 vs 28 years, P < .001) and more received peripheral blood grafts (73% vs 43%, P < .001) but had similar other prognostic factors. The RIC versus full-intensity conditioning groups had slightly, but not significantly, less acute grade II-IV graft-versus-host disease (39% vs 46%) and chronic graft-versus-host disease (34% vs 42%), yet similar transplantation-related mortality. RIC led to slightly more relapse (35% vs 26%, P = .08) yet similar age-adjusted survival (38% vs 43%, P = .39). Multivariate analysis showed that conditioning intensity did not affect transplantation-related mortality (P = .92) or relapse risk (P = .14). Multivariate analysis demonstrated significantly improved overall survival with: Karnofsky performance status more than 80, first complete remission, lower white blood count, well-matched unrelated or sibling donors, transplantation since 2001, age younger than 30 years, and conditioning with TBI, but no independent impact of conditioning intensity. RIC merits further investigation in prospective trials of adult ALL.
authors.affiliation: University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
authors.forename: David I
authors.initials: DI
authors.lastname: Marks
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Waleska S
authors.initials: WS
authors.lastname: Pérez
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
authors.forename: Edward
authors.initials: E
authors.lastname: Copelan
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.forename: Biju
authors.initials: B
authors.lastname: George
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Joerg
authors.initials: J
authors.lastname: Halter
authors.forename: H Jean
authors.initials: HJ
authors.lastname: Khoury
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Klumpp
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Victor A
authors.initials: VA
authors.lastname: Lewis
authors.forename: Philip
authors.initials: P
authors.lastname: McCarthy
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Mitchell
authors.initials: M
authors.lastname: Sabloff
authors.forename: Jeff
authors.initials: J
authors.lastname: Szer
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weisdorf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002066:Busulfan / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012042:Registries; D012074:Remission Induction; D035781:Siblings; D016019:Survival Analysis; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation; D055815:Young Adult
chemical_list: D002066:Busulfan; D008558:Melphalan
references.citation: Bone Marrow Transplant. 2005 Oct;36(8):683-9
references.pmid: 16113673
references.citation: Haematologica. 2003 May;88(5):555-60
references.pmid: 12745275
references.citation: Stat Med. 1999 Mar 30;18(6):695-706
references.pmid: 10204198
references.citation: Haematologica. 2008 Feb;93(2):303-6
references.pmid: 18245655
references.citation: N Engl J Med. 1979 May 10;300(19):1068-73
references.pmid: 34792
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3634-41
references.pmid: 19581540
references.citation: Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14
references.pmid: 19822300
references.citation: Blood. 2009 Mar 26;113(13):2902-5
references.pmid: 19179301
references.citation: Blood. 2008 Feb 15;111(4):1827-33
references.pmid: 18048644
references.citation: Blood. 2007 Apr 15;109(8):3189-97
references.pmid: 17170120
references.citation: Blood. 1989 May 1;73(6):1720-8
references.pmid: 2653460
references.citation: Bone Marrow Transplant. 2006 Oct;38(7):467-75
references.pmid: 16892073
references.citation: Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53
references.pmid: 16545728
references.citation: Blood. 2007 Feb 1;109(3):944-50
references.pmid: 17032921
references.citation: Bone Marrow Transplant. 2008 Apr;41(7):635-42
references.pmid: 18084335
references.citation: Bone Marrow Transplant. 2005 Mar;35(6):549-56
references.pmid: 15756282
references.citation: Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
references.pmid: 19896087
references.citation: Blood. 2008 Jul 15;112(2):426-34
references.pmid: 18398065
references.citation: Blood. 2000 Oct 1;96(7):2419-25
references.pmid: 11001893
references.citation: Haematologica. 2009 Oct;94(10):1399-406
references.pmid: 19648167
references.citation: Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9
references.pmid: 19203728
references.citation: Bone Marrow Transplant. 1998 Jan;21(2):153-8
references.pmid: 9489632